Targeted Drug Delivery System for Kidney and/or Liver Failure Patients Using Human Serum Albumin by Bedingfield, Sean
Utah State University 
DigitalCommons@USU 
Undergraduate Honors Capstone Projects Honors Program 
12-2014 
Targeted Drug Delivery System for Kidney and/or Liver Failure 
Patients Using Human Serum Albumin 
Sean Bedingfield 
Utah State University 
Follow this and additional works at: https://digitalcommons.usu.edu/honors 
 Part of the Biological Engineering Commons 
Recommended Citation 
Bedingfield, Sean, "Targeted Drug Delivery System for Kidney and/or Liver Failure Patients Using Human 
Serum Albumin" (2014). Undergraduate Honors Capstone Projects. 642. 
https://digitalcommons.usu.edu/honors/642 
This Thesis is brought to you for free and open access by 
the Honors Program at DigitalCommons@USU. It has 
been accepted for inclusion in Undergraduate Honors 
Capstone Projects by an authorized administrator of 
DigitalCommons@USU. For more information, please 
contact digitalcommons@usu.edu. 
TARGETED DRUG DELIVERY SYSTEM FOR KIDNEY 





Thesis submitted in partial fulfillment 
of the requirements for the degree 
of 
HONORS IN UNIVERSITY STUDIES 
WITH DEPARTMENTAL HONORS 
in 
Biological Engineering 
in the Department of Biological Engineering 
Thesis/Project Advisor 
Dr. Elizabeth Vargis 
Departmental Honors Advisor 
Dr. V. Dean Adams 
Director of Honors Program 
Dr. Kristine Miller 




Targeted Drug Delivery System 
for Kidney and/or Liver Failure 
Patients using Human Serum 
Albumin 
Utah State University 
Department of Biological Engineering 
Final Report 
Sean Bedingfield, Sara Gertsch, and Stephanie Lawanto 
Dr. Elizabeth Vargis, Faculty Advisor 
10 December 2014 
PROJECT SUMMARY/ ABSTRACT 
Compromised liver and/or kidney function reduces the acceptable dosage of a variety of 
medications that can be administered to patients. These patients still have a need for drugs 
such as nonsteroidal anti-inflammatory drugs {NSAIDs), antivirals, and antibiotics. The project 
goal is to provide a drug delivery system to accommodate these reduced dosage limits with 
added therapeutic benefits to address symptoms of liver or kidney failure. Localized drug 
delivery allows for a smaller, concentrated dose rather than inundating the patient's system 
with the drug of interest. Human serum albumin (HSA) is a researched candidate for drug 
delivery with therapeutic properties. HSA was tested as a drug delivery vehicle for localized, 
percutaneous drug release aided by a displacing compound and changes in temperature and 
ultrasound generated by an external device. Dynamic light scattering (DLS), UV/Vis 
spectroscopy, and optical microscopy were employed in verifying drug binding, release, and 
effectiveness. The optimization of the proposed drug release method, the design of the device 
to promote drug delivery, and the testing of the drug delivery system with in vitro tissue testing 
were performed to validate the designed system. 
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OBJECTIVES/ AIMS 
Due to kidney or liver failure, normally harmless doses of prescription drugs can have toxic 
effects leading to further medical complications (Ing, 1979). Those suffering from kidney and/or 
liver failure frequently suffer related and unrelated ailments, but are restricted on the 
medications and the amounts thereof. Site-specific ailments such as arthritis, localized viral 
infections (viral pneumonia), neuropathic pain, and other illnesses could be treated with 
smaller doses if the treating drug were only made available at the targeted site. 
The project goal is to develop a drug delivery system using human serum albumin (HSA) as a 
carrier for anti-inflammatory, antibiotic, antiviral, and antioxidant drugs. 
In this project, ibuprofen was used as a model drug due to its availability and strong literature 
support for its binding mechanism to HSA. This drug delivery system is unique in using rapid-
sequence, local hyperthermia and ultrasound at a specific site of interest in the body. The 
proposed system is designed for patients with compromised liver and/or kidney function who 
are unable to safely use normal, oral doses of these medication types. 
Objectives 
• Develop a two gel system 
o Investigate and incorporate a drug-carrier binding method using HSA and 
ibuprofen 
o Investigate and incorporate a drug release mechanism for drug delivery using 
competitive binding of omega-3 fatty acid 
• Develop a device 
o Develop a device to activate and amplify the effectiveness of the dose 
DESIGN CRITERIA 
Drug binding and release 
The success of the drug binding is evaluated by the change of absorbance of HSA measured 
with UV /Vis spectroscopy. The criterion for success is a 20% decrease in absorbance from HSA-
only solution to HSA-drug solution, as this is indicative of a 1:1 molar ratio of HSA-ibuprofen 
binding (Su!kowska, 2002; Thumser, 1998). 
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Device 
For the success of the device, there are many criteria that must be met. The designed device 
must be able to successfully facilitate the diffusion of the drug through the skin of the inflamed 
tissue. To do this, the device must be able to alternate between heating and ultrasound. It is 
expected that the heating element of the device will reach 40°C within two minutes (Galantini, 
2010; Lawrence, 1976). The use of ultrasound will be incorporated to further promote diffusion 
of drug across skin. The ultrasound must have a holder that allows for direct contact with the 
skin; the clearance between the ultrasound head and the skin must be no more than one 
millimeter (basically direct contact with aid of ultrasound gel) (Forrest, 1989). The ultrasound 
must also be versatile in regards to position on the affected part of the body; it should have the 
ability to be moved wherever the user deems necessary. Lastly, the device should be non-
invasive as possible and should be convenient and affordable for home use. 
BACKGROUND/ HISTORY 
Prevalence of Patients with liver and/or Kidney Disease 
The Centers for Disease Control and Prevention claims that 10% of adult Americans have some 
level of chronic kidney disease (CKD), and the same percentage suffer from liver disease. Over 
800,000 Americans were treated for end-stage renal disease (ESRD) in 2009 (CDC, 2014; CDC, 
2010). 
Chronic kidney disease is the prolonged reduction of kidney function most commonly caused by 
diabetes, high blood pressure, and advancing age. CKD patients are advised to specifically avoid 
further kidney damage by using anti-inflammatory medication unless advised by a doctor. 
(CDC, 2014) 
Liver disease can be caused by cirrhosis, excessive use of certain pharmaceuticals, infectious 
hepatitis, mononucleosis, the accumulation of fat in the liver, and a host of other illnesses. 
Treatment of liver disease must be specific to the cause, but all patients must be careful not to 
overload the liver's reduced metabolic function. (CDC, 2010) 
Drug Carrier: Albumin 
Human serum albumin is a natural antioxidant that removes reactive oxygen species common 
to those with liver failure, and has drug-binding mechanisms that are well researched (refer to 
Figure 1). It is known that the total amount of albumin in the body is about 3.5-5.0 grams of 
albumin per kilogram body weight, which for a healthy 70 kg adult is roughly 250-300 grams. 
Most of the albumin (120-145 g) is lost in the extravascular space; however, some does get 
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digested (about 1 g) and very little albumin passes through the kidneys. Albumin is synthesized 
in the liver and the rate at which it is synthesized depends on nutrition and the overall health of 
the liver. It is clear that if the liver is diseased, the rate at which albumin is synthesized 
decreases, resulting in an albumin deficiency (Nicholson, 2000). 
This proposed drug delivery system will not only treat inflammation with the use of ibuprofen, 
it will also minimize damage to the liver or kidney due to the localized treatment of drug. In 
addition, albumin can serve as a carrier for a variety of different drugs such antioxidants, 
antivirals and antibiotics. Because albumin is the most abundant protein in the blood, which 
accounts for approximately 55% of protein in the blood plasma, it is expected that the body will 
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Figure 1. Three-dimensional model of the structure of human serum albumin with drug binding 
subsites and common pharmaceuticals to which they correspond (Ghuman, 2005); "2°" refers 
to drugs for which it is a secondary binding site. 
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Drug of Choice: Ibuprofen 
There are over 100 pharmaceutically active compounds shown to bind with HSA, as shown in 
Figure 2 (Zsila, 2011). These drugs vary in form and function. Ibuprofen was selected for initial 
testing of this drug delivery system for its affordable price, the usefulness of site-specific 
delivery, and foundation in literature. Ibuprofen was shown to have a relatively high affinity to 
HSA. It was shown to bind primarily to HSA binding site II (Ghuman, 2005). 
Figure 2. Structure of ibuprofen (top-left), three-dimensional model of ibuprofen bound to 
human serum albumin at subsite IIIA (Ghuman, 2005) 
Displacement Compound: Omega-3 Fatty Acid 
Omega-3 fatty acid is a polyunsaturated fatty acid that is an essential nutrient found in plants 
and animals. This fatty acid is important for normal body metabolism, blood clotting, decrease 
of blood pressure and inflammation. 
HSA has the ability to be a carrier for fatty acid in the blood as fatty acid has been shown to 
bind at multiple binding sites of HSA, some of which overlap directly with the two ibuprofen 
binding sites (Krenzel, 2013). In addition to having multiple HSA binding sites that overlap with 
many drugs, omega-3 fatty acid is an excellent candidate to be used in a drug displacement 
study as it has a higher affinity than ibuprofen to HSA (Bhattacharya, 2000; Reichenwallner, 
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2013). Omega-3 fatty acid is an ideal compound to displace ibuprofen because it is a natural 
substance in the body, therefore, it does not present any harmful side effects to the body. 
Polyunsaturated fatty acids in fish oil are also shown to act as dermal permeation enhancers, 
promoting the transdermal diffusion of ibuprofen and other drugs (Heard, 2003). Increased 
diffusion increases the bioavailability of the drug in the tissue, which could mean more rapid 
results. 
DESIGN STEPS 
Choosing a drug carrier was the first step of this design process. The drug carrier needed to be 
biocompatible, stable and versatile enough to be used with a variety of drugs. Next, a model 
drug was selected to be used as a proof of concept of the designed drug delivery system. The 
model drug must have a relatively high affinity to the drug carrier to ensure binding. 
After a selection of drug carrier and model drug, binding method was developed to bind the 
model drug to the selected drug carrier and drug binding was verified. Release method was also 
verified to quantify the release of the bound drug from its carrier. After the success of drug 
binding and release, a method of drug delivery was carefully considered. 
Based on the selected method of drug delivery, an external device was designed and tested 
against its criteria of enhancing drug delivery. Finally, tissue testing was performed to further 
confirm the effectiveness of the designed drug delivery system. 
Drug Carrier 
Drug carriers including polymeric microspheres, synthetic polymer lattices, nanoparticles, 
protein carriers (particularly human serum albumin), liposomes, and nanofibers were 
considered for the product. Of protein carriers, human serum albumin was selected above 
others for complete biocompatibility and an unrivaled versatility among proteins in the 
transport of multiple drugs. The carrier would need to accommodate the project criteria by 
minimizing the needed medication, granting control of release, allowing versatility in site 
treatment, and allotting for ease in manufacturing. Table 1 is a reflection of the evaluation of 
these drug carriers. 
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Table 1. Alternative drug carriers. Drug carrier selection is determined by how many of the 
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The scores apparent in Table 1 identified human serum albumin as the best option considered 
for the device. The major advantages of albumin are nearly universal biocompatibility and 
versatility with a variety of drugs. Major drawbacks are that albumin must be processed to 
remove lipids before use, and that HSA is only commercially available from animal sources. 
Other carriers that are synthetically manufactured would likely be less expensive in large 
manufacturing. Since this product is highly specialized to a niche group, it was decided to favor 
performance over the high cost of albumin. 
Drug of Choice 
After HSA was selected as a drug carrier, the selection of drug depends on its binding 
mechanism to HSA. Drug selection was considered for best fit to exemplify the benefit of the 
product to patients with compromised liver and kidney function. Groups of drugs were initially 
evaluated for general concern with such patients, demand for the drug, drug availability, 
effectiveness in near-surface treatment, drug safety in handling, and the depth of 
understanding for the functionality of the drug group. Drug group evaluation is shown in Table 
2. 
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Table 2. Classes of drugs thought to possibly fit the criteria required. Drug class selection 
determined by how many of the criteria are met. Some criteria are partially met resulting in a 
score of 0.5. 
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Localized Application 1 0.5 1 0.5 1 0.5 0 
Area of Treatment Near 
1 0.5 0 0.5 0.5 0.5 0 
Skin 
Damaging to Patients 
with Liver/Kidney 1 1 0.5 1 1 0.5 0 
Dysfunction 
Drug Widely Used, 
1 1 1 0.5 0 0.5 0.5 




1 1 1 0.5 0.5 0.5 
Well-Known Mechanism 
1 1 0.5 0.5 0.5 0 0 
for Kidney/Liver Damage 
Drug Availability 1 1 1 0.5 0 0 0.5 
Known Drug-Protein 
1 1 0.5 0.5 0 0 0 
Binding Mechanism 
Drug is Safe to Handle 1 1 1 1 0 0 1 
Score 9 8 6.5 6 3.5 2.5 2.5 
Upon selecting analgesics as the class from which to select the therapeutic agent, criteria were 
changed upon reviewing potential drugs (See Table 3). For ease of procurement, the drug must 
be available without a prescription. As a result, all opioids (codeine, hydrocodone, etc.) were 
removed from consideration. A rating of the effectiveness of the drug as an analgesic, and a 
rating of how little damage is done to kidneys and livers were add to select the drug that would 
be most practical for the application. The change in criteria to find the least damaging drug is an 
effort to provide the most passive drug within a class of drugs where kidney/liver damage is a 
concern. Other criteria were eliminated as the criteria were met by all the compounds. 
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Table 3. Analgesics thought to possibly fit the criteria required. Drug selection determined by 
score based on weighted criteria. 
C: 
QJ 
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Drug is Safe to Handle 1 10 10 10 10 10 10 10 
Drug Availability 2 10 10 10 10 10 10 3 
Drug Widely Used, High 
3 8 10 7 8 8 6 3 
Demand 
Known Drug-Protein 
4 7 10 8 6 8 6 3 
Binding Mechanism 
Most effective 5 6 8 9 7 0.5 0.5 10 
Least Kidney Damage 6 6 10 4 3 7 6 3 
Well-Known Action 
Mechanism 
7 5 8 8 8 8 8 8 
Well-Known Mechanism 
8 5 9 8 9 6 5 4 
for Kidney/Liver Damage 
Score 543 470 451 435 394 313 
From the evaluation of analgesics shown in Table 3, ibuprofen was chosen as the ideal 
candidate based on the criteria. Criteria were rated from the information found in the listed 
references, and evaluated by relative comparison of the drugs. 
Drug Binding Experimentation 
The original system design relied on controlled release of ibuprofen within the bloodstream. 
Binding ibuprofen with a protein stabilizes the drug and reduces activation until the drug is 
released. HSA is a prevalent blood protein often in inadequate concentrations among liver 
disease patients and it serves as a carrier for over 14 drugs. Binding procedures were 
investigated for preparation of an injectable serum. 
Of the six protocols found for binding HSA with ibuprofen, the simplest method was tested first. 
A 10:1 molar ratio of ibuprofen to human serum albumin was prepared with 50 mg of 
ibuprofen. Lyophilized, lipid-free HSA and powdered s-ibuprofen were added to 5 ml distilled 
deionized water in respective order, giving the HSA two hours to dissolve before adding 
ibuprofen. After an additional six hours on a shaker table at room temperature, absorbance 
was measured. HSA is known to contain a single fluorescent tryptophan near the primary 
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binding site, which was employed for the binding verification using shifts in fluorescence 
(Thumser, 1998). It was expected that fluorescence would decrease when the drug was bound 
to the protein (Thumser, 1998). Fluorescence studies and UV-VIS spectrophotometry were 
employed at excitation wavelengths of 280 and 295 nm with corresponding emissions at 340 
nm and 350 nm. 
Table 4. Resulting fluorescence of free ibuprofen, pure albumin, and an ibuprofen/albumin 
solution at 325 nm; no hypothesis is no change in fluorescence 
Mean Standard 
Std Err 



















2981 3.00 1721 
3054 3.00 1763 














Figure 3. Fluorescence data with HSA showing a drop in fluorescence once mixed with 
ibuprofen, indicating drug-protein binding; Error bars represent standard deviations of triplicate 
results 
As shown in Table 4 and Figure 3, fluorescence showed a statistically significant reduction with 
99% confidence in fluorescence, indicating drug-protein binding (Thumser, 1998). This method 
was selected for ease of execution. Two methods incorporated removing lipids from HSA, which 
was skipped by ordering lipid-free HSA. Another three methods involved altering the HSA 
conformation, which was avoided for simplicity of the product. A major advantage of using 
standard HSA is the greater extent of the published research on its diffusive and chemical 
properties over any altered version of the protein. Some disadvantages of selecting lipid-free, 
unaltered HSA are a weaker HSA-ibuprofen bond, the increased cost of purchasing lipid-free 
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HSA instead of chemically removing lipids in-house, and the dearth of industrially available non-
animal sources. 
After the decision was made to use transdermal delivery, there were concerns that the gel used 
for drug loading and ultrasound would cause premature ibuprofen release or bind with the 
ibuprofen independently. Testing was necessary to verify the employed gel would act as an 
inert medium. 
Testing of HSA-bound ibuprofen fluorescence behavior suspended in the selected guar gum gel 
was compared to HSA, ibuprofen in gel and water, and HSA-bound ibuprofen in water. Since 
the guar gum gel is aqueous, the desired dosage of 50 mg/ml of ibuprofen was achieved by 
preparing a doubly thick of gel, and using half the needed water to perform the binding 
protocol before mixture with gel. Fluorescence of the samples was again tested under the same 
conditions as water-based binding confirmation testing. Results are shown in Table 5 and Figure 
4. 
Table 5. Fluorescence comparison at 320 nm of compounds in water and compounds (IBP= 
ibuprofen; HSA = Human Serum Albumin; HSA-IBP = HSA-bound ibuprofen) in gel; no hypothesis 
was no change in binding 
Mean Percent 
HSA+IBP Standard Std Err Hypothetical 
P-value Fluorescence from a 
Sample Matrix Deviation {%) (%) Mean 
HSA in Gel 
Water 24.70 2.63 1.52 24.70 
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Figure 4. Fluorescence comparison at 320 nm of compounds in water and compounds (IBP= 
ibuprofen; HSA = Human Serum Albumin; HSA-IBP = HSA-bound ibuprofen) in gel; Error bars 
represent standard deviations of triplicate results of triplicate sample; unseen error bars have a 
negligible standard deviation 
As shown in Table 5, no statistically significant difference was found between fluorescence 
behavior in water and gel solutions, which indicated retained binding behavior in both matrices. 
Drug binding was found to be compatible with the selected gel. 
The final concern with drug binding was the reversibility of the drug binding. Successful drug 
release was the final requirement for an effective drug binding strategy. 
Drug Release Experiments 
Initially, the HSA-drug compound was planned to be injected and released through the use of 
the device. The drug was planned to be released through an increase and decrease in 
temperature followed by ultrasound. These heating and cooling cycles polymerize HSA, causing 
a release of the drug. Ultrasound was proposed to promote drug diffusion and bioactivity in 
localized drug release from HSA. 
Experiments were performed to test if HSA polymerization seen in literature when cycling 
between 75° C and 25° C could be observed after only five minutes of external heating at 75° C 
(Wetzel, 1980). Results are shown in Table 6 and Figure 5. Experiments at all lower 
temperatures and heating times showed no statistically significant change in HSA size 
distribution. 
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Table 6. Measurements of albumin aggregate diameter by dynamic light scattering (DLS); the 
null hypothesis was no change in aggregate size. 
Mean Values of 
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Figure 5. Dynamic light scattering (DLS) measurement of size distribution before heat cycling 
(left), and after heating with 75° C for 5 minutes before cooling to 25° C (right) 
It was found that a minimum of 75° C was needed to polymerize the HSA to release ibuprofen. 
However, the temperature was deemed too hot for the skin surface. With 50° C considered the 
maximum tolerable temperature for skin, heating cycling of 50° C for 35 minutes was still not 
adequate to cause polymerization or release ibuprofen from HSA. It was then concluded that 
HSA could not be denatured to release ibuprofen within the temperature range that is tolerable 
for the skin. 
In addition, the first approach of the drug delivery system was not reliable as there was not 
enough data on the circulation time of HSA-drug compound in the body. Moreover, it was not 
an efficient design as the patient would need to release the drug at his or her own time after 
being injected with the HSA-drug compound. 
Because drug release through the polymerization of HSA through changes in temperature was 
not adequate in releasing ibuprofen, a second approach of drug release mechanism was 
needed. Several different alternatives were explored such as pH changes, pressure changes and 
electrical conduction. However, site-specific changes of pH in the bloodstream would be 
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invasive, costly, and would likely have adverse effects on the body. In addition, adjusting the 
pressure applied to the protein would require more complicated equipment. Electrical 
conduction was also another possible alternative to induce drug release. Applying voltage to 
the HSA was expected to change the conformation of the protein, releasing ibuprofen. 
However, this was not a feasible method for use in the body. 
Transdermal drug release using a displacement compound was then selected as the new 
release strategy. There was also consideration of removing albumin entirely from the project. It 
was decided that albumin could still play the following roles as the drug carrier in a transdermal 
system: 
• Albumin can stabilize a suite of pharmaceuticals in aqueous solution. 
• Albumin could mitigate bioactivity until application of pharmaceuticals, such as 
hormonal derivatives, could be hazardous to handle. 
• Region of drug delivery could be tuned by adjusting the time interval between 
introduction of the HSA-bound ibuprofen and the introduction of a displacing agent. 
Various displacement compounds were considered for drug displacement as shown in Table 7. 
Because HSA is a natural carrier of fatty acid in the blood, fatty acid was deemed sufficient to 
fulfill the role of a drug displacement compound. Various antioxidants, warfarin, diazepam and 
bilirubin were also considered for their known binding site that overlap with binding site of 
ibuprofen in HSA. The use of salicylic acid as a drug displacement compound was frequently 
studied in literature, however, its binding site in HSA does not overlap with that of ibuprofen. 
Finally an enantiomer of ibuprofen was also considered to be a potential candidate of drug 
displacement compound, however, the risk of overdose compromised the safety of the 
designed drug delivery system. 
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Table 7. Alternative displacement compounds for drug release experiment. Displacement 
compound is selected by the highest total score. 
Safety 
Affinity to HSA (> IBP) 
Known Binding 
Mechanism 
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Fatty acids were found to most closely meet the criteria for a displacing comment with a high 
binding affinity with HSA, binding site overlap, depth of understanding for HSA binding, and 
compound availability. As these fatty acids were derived from fish oil, there is a variety of 
unsaturated fatty acids. The unknown variety in fatty acids may be a source of undesired 
variability in effect. This risk was accepted as the product design calls for excess of fatty acids, 
and variability should be minimally influential on product performance. 
A major role of albumin in the body is safe lipid transport through the bloodstream. Albumin 
has seven high-affinity fatty acid binding sites as shown in Figure 7. It was decided to try 








Figure 7. Map of fatty acid binding sites on human serum albumin (Reichenwallner, 2013) 
Fatty acid binding sites FA3, FA4, and FA6 depicted in Figure 7 directly overlap with ibuprofen 
binding sites. Distilled fish oil was chosen for availability and the blend of eicosapentaenoic acid 
(EPA) and decosahexanoic acid (DHA) fatty acids. 
Fatty acid displacement would require a separate introduction of the oil at the time of 
treatment. Like an epoxy, a two-part gel system would be necessary to cause competitive 
binding and displacement at the time of use. This creates an undesirable added step in 
complexity of treatment, but also provides added control over drug delivery that could be 
considered advantageous. Further literature review indicated that fatty acids from fish oil in 
excess would also facilitate transdermal drug diffusion (Heard, 2003). 
Another approach for measuring compounds in liquid solution is liquid chromatography -
tandem mass spectrometry (LC-MS/MS). Tandem mass spectrometry allows for some 
compounds to be accurately tested at concentrations of 10 ng/L (Hernando, 2006). The binding 
and release of ibuprofen was verified by measuring the ibuprofen in a solution before HSA 
introduction, after binding with HSA, and after displacement with fish oil. 
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Aqueous solutions of ibuprofen were prepared at 1.5 mg/ml concentrations in triplicate, and 
passed through 0.45 µm Frisenette PVDF filters. A sample of each solution was diluted by a 
factor of 100, and measured for initial concentration. HSA was added to the solutions for an 
HSA concentration of 24 mg/ml (for a 10:1 Ibuprofen to HSA molar ratio) and placed on a 
shaker table at room temperature for 8 hours. Samples were taken, diluted, and measured 
again in the same manner. Finally, molecularly distilled fish oil was added in a calculated molar 
excess at a concentration of 32 mg/ml, placed on a shaker table for 6 hours before final 
measurement. Triplicate samples were measured in triplicate. 
Concentrations were determined on an Agilent Triple Quad LC/MS 6490 at the Utah Water 
Research Laboratory. An Agilent Zorbax Eclipse XDB C-18 Rapid Resolution HT column {50x4.6 
mm i.d.; 1.8 µm particle size) was employed. The column temperature was set to 70 •c, and a 
30 µL injection volume. A 40:60 volumetric ratio of 0.1% formic acid and acetonitrile {pH=3.0) 
was used as the mobile phase at a flow rate of 0.15 ml/min. Analysis was done using 
electrospray ionization {ESI) in positive ion mode. Drying gas flow was 9.0 L/min and drying gas 
temperature was set at 350 •c. Capillary voltage was set to 4000 V, and nebulization pressure 
was at 35 psi. Fragmentor and collision energies were 380 V and 20 V, respectively. The 
precursor ion and quantifier ion mass-to-charge-ratio (m/z) were respectively 204.9 and 161.2. 
The detection limit for ibuprofen in sample matrix was 202.9 pg on column {24.29 pg/µL), 
qualified by a signal-to-noise ratio greater than 10. The identified retention time with this 
method for ibuprofen was 10.08 minutes. 
Ibuprofen concentration standards supplied through Agilent were used to generate the 
calibration curve shown in Figure 8. While standards below 5 µg/L were unreliable, an 
appropriate quadratic fit was found for the range of 5 - 100 µg/L. Measured concentrations are 
also included in Table 8. 
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Ibuprofen -10 Levels, 3 Levels Used, 10 Points, 3 Points Used, 0 QCs 
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Figure 8. Calibration curve for LC-MS/MS measurement of ibuprofen in water 





































Ibuprofen concentrations for each sample are given in Table 9, Figure 9, and Figure 10. There 
were no observed deviations in preparation between the tested samples. Solution treatments 
were executed as discussed above. 
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Figure 9. LC-MS/MS measurement of ibuprofen solutions through the drug binding and 
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Figure 10. LC-MS/MS measurement of ibuprofen solutions through the drug binding and 
displacement treatments; Standard deviations of each sample were all less than 0.01 µg/L. 
Using a one-sample t-test, it was found that the null hypothesis - that there was no release of 
ibuprofen from HSA - could be rejected with 95% confidence. This indicates that there is 
ibuprofen released from fatty acid displacement. It was decided that a one-tailed t-test was 
appropriate for use with the manageable size of the data used, and the consistent increase 
between samples after displacement. 
While not as apparent in Figure 9, Figure 10 illustrates a consistent trend of ibuprofen reduction 
after the binding process, and increase after displacement. The significance of the release is 
further demonstrated in Table 10 by the mean percent of ibuprofen released when compared 
to the reduction from the binding step, 51.45%. 
Delivery Approach 
Means of drug delivery were evaluated according to the parameters given in Table 10. 
Transdermal diffusion was considered for its localized treatment and minimal invasiveness. 
Bloodstream injection and drug-loaded hydrogel were initially considered for their possibility of 
local concentration of the drug dosage. Finally, oral ingestion was seen as common, but 
considered for its effective method of drug delivery. 
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Safety from Accidental 
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Overdose 
Ability to Self-Administer 
4 7 7 4 10 1 
the Drug 
Minimally Invasive 
5 6 10 7 10 1 
Implementation 
Score 345 244 172 171 
Bloodstream injection was initially selected to be a means of drug delivery in this project 
because it provided a reliable way of drug delivery. However, after the drug release method 
changed, drug delivery by means of transdermal diffusion was selected. In addition, 
bloodstream injection was deemed inefficient as the patient would need an invasive clinical 
administration to acquire the HSA-drug compound in the body before releasing it later at home. 
As shown in Table 10, transdermal drug diffusion was determined to be the best considered 
means of drug delivery for this project. Primary strengths of transdermal delivery were the 




The overall objective is to design a device that is noninvasive, comfortable, and affordable. 
Originally, the design idea was to focus on application to the arm, but also have the flexibility to 
design products for the leg, shoulder, and hand. The plan for the device was to have a tight, but 
breathable, material and elastic bands sewn in at the wrist; this would provide a more 
controlled environment as well as controlled blood flow in the desired area. Two holes, at the 
inside of the elbow and inside of the wrist would provide areas where ultrasound could be 
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applied. The ultrasound would have been mounted on the forearm, with the ability to pivot and 
to move laterally with the aid of a notch system. Small heating pads and cool water pumps 
would be applied both on the upper arm and lower arm, allowing the user to choose which area 
he or she would like to treat. A depiction of this design can be seen in Figure 11. Another goal 
of this device was to design a product that could be programmable and mostly automatic. 
Figure 11. First product design that incorporated an ultrasound (seen in gray) and an LCD 
screen (seen in blue) as well as heating and cooling elements inside that ran along both the 
upper and lower arm. A hole near the wrist area for ultrasound application can also be seen. 
Since the incorporation of ultrasound was crucial in the overall design of the device, it was 
important that the ultrasound be mounted in close proximity to the arm as well as have 
flexibility in position. Therefore, the design of the ultrasound holder came from the idea that 
every person's arm length is different and that there were two spots within the sleeve design 
where ultrasound could be applied, so a pivoting and locking system was needed to fulfill the 
above problems. This original holder design can be seen in Figure 12. 
Figure 12. First design of the ultrasound holder. This holder consists of multiple locking 
notches and required the holder to have a matching piece to ensure proper locking. 
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When designing the ultrasound holder, it was obvious that this first design was not an effective 
design for many reasons: 
• It relied on the user's ability to push and pull the holder in and out of the locking 
mechanism. The repetitive pushing and pulling would wear the piece out more quickly 
in terms of keeping the original shape. This motion would also cause extra movement 
and pressure, which could cause further pain to the individual. 
• It was too complicated for its intended function; it required too much work for the user, 
when the whole purpose was to make it easier to adjust the position of the ultrasound. 
• This system would not be removable; the holder would be protruding out of the 
armband, which could become uncomfortable over time, especially if the user did not 
want to use the ultrasound. 
• The 3D printer would have had a hard time with this design because of the long slender 
parts as well as the holes within the piece, and it was crucial that the ultrasound holder 
be 3D printed. 
• This design was based on the first design for a full-length armband. 
Second Design 
After considering the fact that the first design was dependent on the injection of the protein-
drug complex, had a lack of flexibility to be solely used at home and heavily relied on the 
circulatory system (which made the objective of controlled drug delivery not possible), it was 
obvious that a new design was needed to accommodate the original objective of creating a 
noninvasive and portable device with the ability to control drug delivery. A more feasible 
approach to the problem was to depend on the diffusion of the drug through the skin. In order 
to facilitate this, the second device design consisted of the following: 
• A simple cloth band (similar in shape to a blood pressure band) 
• A heating element 
• A cooling element 
• A sheet of copper (to help heat transfer) 
• An ultrasound with a Velcro holder that could be adjusted to anywhere on the arm. 
Similar to the first design, the focus was on the application to the arm while allowing flexibility 
to design for any other part of the body. 
Like the original design, the inclusion of the ultrasound was key in further facilitation of 
transdermal drug delivery. Because the first ultrasound holder design was not ideal, it was 
necessary to design a holder that could be removable, more user-friendly, and less likely to 
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wear out. As seen in Figure 13 (left), this design incorporates all of the parameters mentioned 
previously. In comparison to the first holder design this design was: 
• Easily removable, meaning the user can decide whether he or she wants ultrasound or 
not. 
• The ease of moving it is simple; the user just has to undo the Velcro, move the 
ultrasound to the area where he or she needs it, and then tighten and Velcro to secure 
it. 
• This design was also much less likely to wear out; it did not rely on the user forcing it 
into matching holes. Instead, it relied on an elastic or rubber band to hold the 
ultrasound on the holder. 
• Because this holder was easily removable and did not rely on extra force to hold it in 
place, it was deemed more user-friendly than the first design. 
However, even though this design met the above criteria, it did not have the capability of 
securely holding the ultrasound in place. Because of this flaw, it was necessary to add a slight 
curve to the top of the holder. 
Figure 13. Second design of ultrasound holder. This design includes a slit for Velcro, and two 
arms to attach an elastic band, which keeps the ultrasound on the holder. The image on the 
right is the same design just with a slight curve to better hold the ultrasound. 
As seen in Figure 13 (right), the addition of the curve to the top of the holder made it much 
easier for the ultrasound to fit to the holder, therefore making it more stable. Once this design 
was 3D printed and tested on the arm, the following problems were observed: 
• It could not provide the ultrasound sufficient contact with the skin; when the ultrasound 
was placed on top of the holder, it rested about one centimeter above the skin, which 
did not meet the criteria of having a clearance of one millimeter or less. 
• The holder was not very stable when strapped to the arm; this was not ideal because 
any additional movement could not only cause more pain to the user, but also position 
the ultrasound in an undesirable location on the affected area. 
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This led to another change in the overall design of the device as well as a change in the design 
of the ultrasound holder. 
Third Design 
Even though the second overall design fit most of the criteria, there was still one problem 
regarding the use of the cooling element. Originally, the cooling element was essential in the 
heating and cooling cycles for HSA polymerization and the release of ibuprofen. The cooling 
element was kept in the second design for inflammation purposes because cooling helps reduce 
inflammation. However, the cons of incorporation of this element outweighed the pros. The 
negatives of the cooling bladder are as follows: 
• It would require more energy to power the device, which could become costly. 
• The use of water or other cooling fluid would have been involved, which if a leak were 
to arise, it could damage electrical components as well as introduce the risk of 
electrocution. 
• It would be cumbersome to have to carry around a cooler, which defeats the purpose of 
the device being easily portable, not to mention that some of the consumers might not 
have the ability to lift said device; therefore, the third design phases out the integration 
of the cooling element. 
In terms of the ultrasound holder, it was crucial that the problems with the clearance between 
the ultrasound and the skin as well as stability of the ultrasound on the body part were 
addressed in the next design. As seen in Figure 14, the third design incorporated a curve and an 
inclined surface (roughly 21 degree incline) in order to maximize the contact of the ultrasound 
with the skin. This design also included a wider slit for Velcro and a bigger base for better 
stability. When tested on a human arm, it was obvious that the ultrasound was touching the 
skin; it was also obvious that when the arm moved back and forth, the ultrasound stayed in 
place, therefore maintaining stability and contact with the skin. It was decided, based on the 
above observations, that this design would be the final design for the ultrasound holder. 
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Figure 14. The third design incorporated a more stable base as well as an inclined and curved 
top to maximize the contact of ultrasound with the skin. 
Even though a design for the ultrasound holder had met the specified criteria, the overall 
device was still lacking the following components: 
• It was difficult to draw the design, and it was even more difficult to build a prototype, 
which building a prototype was one of the crucial steps for the success of the project. 
• There was not an easy way to incorporate the microcontroller and the LCD screen into 
the armband without making the whole product bulky and cumbersome. 
• An ultrasound should have the ability to move around, since it should not rest in one 
place for an extended period of time; the design would not have allowed the ultrasound 
to move, which could cause additional problems for the user. 
Ultimately, a new design was needed to allow ease of prototyping, the ability to house the 
microcontroller and LCD screen, and the potential to be easily moved around the surface of the 
skin. 
Fourth Design 
Using the overall objectives and the flaws of the previous designs as a guide, a fourth design 
was created. Instead of relying on an armband to ensure proper delivery of the ibuprofen, it 
was easier to create a hand held device. This design included: 
• A laundry-iron type mechanism where the heating and the ultrasound were on the 
bottom of the device along with a layer of polydimethylsiloxane {PDMS) to increase the 
efficiency of the ultrasound as well as provide a barrier between the heating element 
and the ultrasound. 
• Places for the microcontroller and the LCD screen as seen in Figure 15, unlike a few 
previous designs that could not incorporate these elements. 
• The last design of the ultrasound holder because it had fit the criteria so well. 
• A beveled hole for the ultrasound and holes for tubes of gel and LED lights as device 
status indicators. 
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In comparison to the other devices, this one solved the biggest problem of a stationary 
ultrasound component; this device allowed the user to move the ultrasound (along with the 
rest of the device) to wherever he or she deemed necessary. Another positive to this design 
was that the handle to move the device was the actual ultrasound handle, therefore ensuring 
constant movement of the ultrasound head. Fortunately, this device was 3D printed and tested 
with the necessary components. However, after this design was 3D printed, it was obviously 
too bulky for its intended purpose. A fifth and final design was deemed necessary to make the 
product more user-friendly. 
Figure 15. Fourth overall device design. As seen above, there is room for an Arduino and an LCD 
screen in the front. There is a beveled hole for the ultrasound to ensure proper contact with the 
skin. The holes in the top of the device are for tubes of gel as well as small holes for three LED 
lights. 
Fifth Design 
When comparing the fourth design with the fifth (and final) design, the differences between 
them are quite small, however the fifth device was designed to be much slimmer; this design 
feature makes the device easier to hold and maneuver, allowing it to be more user-friendly. 
Similar to the fourth device design, this new design has a space underneath where the copper, 
the heating pad, a layer of PDMS, and the temperature probe can go in order to provide 
sufficient heating and ultrasound. Differences between the two designs include: 
• A parallel LCD screen opening to make the device slimmer. The screen opening in the 
fourth design was perpendicular, which had contributed to the extra width of the 
device. 
• A wider beveled hole (roughly twice the size) to ensure proper contact with the skin. 
• A forward shift in the position of the ultrasound holder in order to maximize the amount 
of handle present; this change was made to ensure the consumer would have a 
comfortable grip. It would also enable the device to be easily manipulated to wherever 
the user considers necessary. 
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• A slight decrease in the length of the device because the Arduino is mounted on the side 
of the device instead of on the bottom. With that said, the device needed to be slightly 
taller to accommodate the placement of the Arduino on the walls of the device (refer to 
Figure 16). 
Figure 16. Fifth overall device design. As seen above, this final design features a slimmer look 
without compromising on functionality. 
When the different designs are compared to each other, it was obvious that the fourth and fifth 
design were the best because they were so similar, however the fifth design was slightly better. 
Looking at Table 11, the fourth and fifth designs ranked the highest in consistent performance, 
versatility, durability, and ease of use categories; they also tied with the second and third 
design in the noninvasive and power consumption categories. As was described earlier, there 
were many pros and cons to each design. The first design was an acceptable first design 
because it met a few of the selected criteria, however it still required an invasive treatment; it 
also was not very versatile or easy to use. The second design was much better in comparison to 
the first because it was a bit more versatile and it was noninvasive. Unfortunately, it included a 
cooling element that was not needed and it did pose a slight threat of possible electrocution if 
the water pump were to leak. The third designed phased out the cooling element hazard and 
focused on heating and ultrasound. This product was very noninvasive, safe, durable, and 
affordable, although it could not be 3D printed, which was a critical part for building a 
prototype. It also did not allow for movement of the ultrasound, which could cause a variety of 
additional problems. Taking the negatives of prior designs, the fourth and fifth designs were 
created. These designs were very versatile, more durable, and the easiest to use. The three best 
parts of these designs were they allowed for ultrasound movement, were able to be 3D printed, 
and had housing for all the necessary components of the automated system (Arduino, LCD 
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screen, lights, temperature probe, etc.). With that said, the fourth design was still too bulky, 
therefore making the fifth design slightly more versatile and easier to use. 
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In vitro tissue testing was incorporated into the design process as it provided a reliable and 
valuable test to evaluate the drug functionality in a more relevant biological setting. Primary 
cells are cells that are extracted directly from living tissues of interest; therefore, they provide a 
more representative model to cells in vivo. Primary fibroblast cells was used because they are 
more robust and provided a longer culture life span when compared to other primary cells 
(Takahashi, 2006). 
Although in vitro drug release test provided an excellent way to evaluate the effects of the drug 
on cell culture, it did not provide an accurate estimation of how much of the drug was able to 
diffuse through skin in vivo. The second phase of tissue testing was added to determine the 
diffusivity properties of the gel containing Ibuprofen through skin. The use of a natural or 
artificial skin layer is a common method to evaluate the efficiency of drug delivery method in 
drug release studies. The use of a porcine skin layer was then incorporated into the tissue 
testing to mimic the human skin barrier and to simulate the diffusion of the drug through skin. 
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The original design relied on changes in temperature to release ibuprofen. The goal of this 
project was to show that after treatments of HSA-ibuprofen compound by changes in 
temperature, ibuprofen was able to be released and perform through the inhibition of 
inflammation in tissue culture. In tissue engineering, exposure of cell culture to hypoxia and 
inflammatory cytokine are two common methods of inducing cell inflammation in vitro. In the 
first phase of tissue testing experiment, exposure to hypoxia was chosen for its feasibility in 
inducing inflammation in cell culture. Oxygen is a vital substance to life because of its role in the 
final acceptor of electrons in the electron transport chain. Stress caused by a lack of oxygen has 
been shown to affect cell survival and viability (Yun, 1997). 
Exposure of cells to hypoxic condition is commonly done by placing the cell culture flask in an 
incubator with 2% or less oxygen concentration. In the first phase of tissue testing, hypoxic 
condition was achieved by covering the cell culture flask using plastic paraffin film to prevent 
the flow of oxygen into the flask in the incubator. To determine the time it takes to effectively 
induce inflammation, 3T3 fibroblast cell was exposed to hypoxia for 5 hours, 12 hours, 24 hours 
and 48 hours. The 24-hour exposure was found to be the most effective in inducing 
inflammation compared to the 5 and 12-hour exposure as it significantly decreases the cell 
population. On the other hand, 48-hour exposure led to complete cell death as shown in Table 
12. 
Table 12. Average cell population count after hypoxia induced inflammation. 
Average Cell Population ( 10 6 cells) 
Experiment Control 5 hours 12 hours 24 hours 48 hours 
1 2.8 2.76 2.52 1.5 0 
2 3.3 2.98 2.84 1.62 0 
3 3.04 2.96 2.8 1.44 0 
4 2.98 2.74 2.2 1.12 0 
Averaqe 3.03 2.86 2.59 1.42 0 
St. Dev. 0.21 0.13 0.29 0.21 0.00 
Cells were exposed to solutions of ibuprofen, ibuprofen+HSA compound and 
ibuprofen+HSA+fatty acid complex. T75 polystyrene flask was seeded with 7x104 cells on day 1 
of the tissue testing experiment. Cells were allowed to grow for 48 hours. On day 3, the flask 
was covered with paraffin film to prevent the flow of oxygen and was subjected to hypoxic 
condition for 24 hours. After 24 hours, the cells were trypsinized and stained with trypan blue 
dye to calculate the cell population count as shown in Table 13. 
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Table 13. Average cell population count after cell exposure to ibuprofen, ibuprofen+HSA 
compound and ibuprofen+HSA+fatty acid. 
Average Cell Population (10 5 cells) 
Experiment Control lbp lbp+HSA 
lbp+HSA+Fatty 
Acid 
1 14.2 15.9 14.05 15.1 
2 15.1 15.55 13.95 16.15 
3 14.9 14.1 14.2 15.2 
4 14.75 15.5 14.8 16.3 
Average 14.73 15.26 14.25 15.68 
St. Dev. 0.38 0.79 0.38 0.54 
Because the mechanism of drug release changed, a second phase of tissue testing was added to 
prove the release and the diffusion of ibuprofen. While the first phase of tissue testing provided 
a good support that the effectiveness and properties of Ibuprofen remained the same, it did 
not provide enough proof that the drug release was a result of the drug delivery treatments. In 
the second phase of tissue testing, an endotoxin called lipopolysaccharide was used to induce 
inflammation in cell culture. Lipopolysaccharide is a cell wall component found in gram-
negative bacteria, which plays a role in the process of septic shock (Martich, 1993). 
The second phase of tissue testing included the use of a natural skin layer as final step to 
determine the diffusivity of the drug delivery complex. A porcine skin layer was used to cover a 
petri dish containing cell culture to mimic human-skin interface. Treatments including the 
application of gel containing the HSA-lbuprofen-fatty acid compound and also ultrasound were 
applied on the skin. The skin was treated with heating pad for 2.5 minutes and followed by 
ultrasound for 5 minutes. Treatment on the porcine skin using gel that contained only the fatty 
acid without the HSA-lbuprofen compound was used as a method control in addition to a 
negative control as seen in Table 14. Treatment on the porcine skin using gel and ibuprofen-
HSA-fatty acid complex showed the highest average cell population count as shown in Figure 
17. 
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Figure 17. Average cell population after treatment on natural porcine skin layer; Error bars 
represent standard deviations. 
Statistical analysis shown in Table 15 revealed that treatment on the porcine skin using gel 
which contained the lbuprofen-HSA-fatty acid complex significantly increased the cell 
population. Because the P-value is less than the significance level of 0.1, it can be concluded 
that the null hypothesis that the treatment does not increase the cell population could be 
rejected with 90% confidence interval. In addition, the method control showed that there was 
no statistically significant difference in cell population compared to the control. 
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Table 15. Statistical analysis of tissue testing result. 



























The focus of the modeling section is to create a 20 model of diffusion of ibuprofen through 
skin. This section will be divided into three smaller models: 
1. Model of heat transfer from the drug delivery system device 
2. Model of competitive binding of ibuprofen and fatty acid in HSA 
3. Model of diffusion of ibuprofen across skin 
Model of Heat Transfer 
This model focused on the heat transfer both on the surface of the skin as well as within the 
body and how external heating affects the transdermal delivery of the drug of interest. When 
developing the model, a few assumptions were made. The body part of interest was the lower 
arm, which was to be modeled as a cube. Convection on the surface of the arm was negligible, 
and radiative heating from the body was ignored. It was assumed that a layer of dead skin cells 
could be described using a 20 model with changes in two positions ("x" that runs parallel with 
the skin and "z" that goes into the skin) as well as changes in time, which can be seen in the 
following equation: 
8T = a [82T + 82T] 
ot ox2 oz2 
where a is the thermal diffusivity; x, the change in distance parallel with the skin; and z, the 
change in distance within the skin layers (Bruch, 1974). On the surface of the skin, without the 
influence of the device, the temperature was assumed to be 30 °C when the temperature of the 
surrounding air was 25 °C (Cross, 2008). Because there was not any external heat being applied 
to the surface of the dead cell layer, this layer was assumed to be in steady state, therefore 
following a linear temperature distribution, assuming the live cell layer remained at a constant 
37 °C. The equation used for the linear temperature distribution is as follows: 
Ti - Tsurf 
Td(z) = k + Tsurf zd. 
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where Td(z) is the temperature of the dead cell layer at a given depth, z; T., the temperature of 
the top of the live skin layer; T,urt, the temperature of the top layer of skin when surrounding air 
temperature is 25 °C; zd, the depth of the dead cell layer; and k, the depth iteration. 
For the live cell layer, a 1D heat transfer model for blood flow was created using the following 
modified Pennes' bioheat equation: 
ST S
2
T [ T-Ta] 
St = a sxi + Wo + W1 Ta (Ta - T) 
where Ta is arterial blood temperature; T, local temperature of tissue; a, the thermal diffusi_vity; 
w 0 , temperature-independent (basal) perfusion rate (volumetric flow rate of blood per volume 
of tissue); w 1 , temperature-dependent (vasodilation) perfusion rate; and x, the distance from 
the heated surface (Lakhssassi, 2010). For modeling purposes, Ta and w 1 were kept constant. 
The thermal diffusivity was also assumed to be the same for both dead and live skin cells. 
In order to combine the two models, it was assumed that the top layer of the live cell layer 
would be equal to the bottom layer of the dead cell layer. Therefore running them together 
could give an approximation about the temperature distribution throughout the skin when a 40 
°Cheating element is applied to the surface of the skin. From preliminary runs of the model, it 
is apparent that the skin approaches 40 °C within the allotted time of 150 seconds (2.5 
minutes). 
As seen in Figure 18, when heating a section of an arm with an external temperature of 40 •c, 
the temperature through the layers of skin quickly approaches this external temperature. 
Between time equals O and 60 seconds the most heat transfer occurs between the surface of 
the skin and between the tissue and blood vessels. Once the time reaches 90 seconds and 
beyond, the difference in temperature become much less, indicating equilibrium. From this 
model, it was discovered that the inside layers of the skin will approach 40 •c, therefore 
indicating that the design device has the potential to further promote drug diffusion. As a note: 
the horizontal axis labeled "x (mm)" is the direction parallel to the arm, the depth axis labeled 
"z (mm)" is the depth into the skin, and the vertical axis labeled "Temperature (C)" is the 
temperature values used to help create the temperature distribution. 
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Figure 18. Temperature distribution of 2D surface heat transfer with 1D blood vessel to tissue 
heat transfer. As seen above, the temperature approaches equilibrium rather quickly, 

















• ln I 
• 1r.-
• 1• J:i 
•JJ.J.I 
■ U ll 
• 11 ti 
• ,u •• 
Model of Competitive Binding of Ibuprofen and Fatty Acid with HSA 
The competitive binding component is based on molecular interactions upon application and 
blending of the two inert gels containing HSA-bound ibuprofen and distilled fish oil fatty acids. 
The approach takes the dissociation constant (Kd) values for HSA-ibuprofen and HSA-fatty acid 
binding {Hage, 1995; Simard, 2006), the recorded treatment temperature profile, and published 
minimum time periods to equilibrium (Baroni, 2001), and influence on Kd by temperature 
(Brodersen, 1974) over time to calculate concentrations of free and bound molecules. 
Values from early mass diffusion were calculated concurrently for improved accuracy in both 
binding and diffusion calculations. 
The following equations were applied for the concentration of albumin-bound and free 
ibuprofen, eicosapentaenoic acid {EPA) fatty acid, and docosahexaenoic acid (DHA) fatty acid as 
applied in other published applications {Wilkinson, 2004). 
The following equations regarding the concentrations of Ibuprofen, Albumin, EPA, DHA and 
their respective bindings are given. These concentration models were then developed in 
graphical form (see Figures 19 and 20). 
model. 
L1 = Ibuprofen 
L2 = EPA 
L3 = DHA 
R = Albumin 
L1 R = Ibuprofen - Albumin 
d [Li] 
~ = -kass[Li][R] + kdiss[L1R] - kass[L1HL1R] + kdiss[L2R] + kdiss[L3R] 
d [R] 
~ = -kass[L1][R] + kdiss[L1R] 
d [L1 R] 
_d_t_ = kass[L1][R] - kdiss[L1R] - kass[L1HL1R] + kdiss[L2R] + kdiss[L3][R] 
d [L2 R] 
~ = kass[L1HL1R] - kdiss[L2R] - kdiss[L3R] 
The EPA and DHA concentration equations were fashioned following the Ibuprofen 
d [L2 ] 
~ = -kass[L2][R] + kdiss[L2R] - kasslL2HL2R] + kdiss[L1R] + kdiss[L3R] 
d [L3 ] 
~ = -kass[L3][R] + kdiss[L3R] - kass[L3][L3R] + kdiss[L2R] + kdiss[L1R] 
d [L2 R] 
~ = ka55 [L1HL1R] - kdiss[L2R] - kdiss[L3R] 
37 
The models for were then analyzed using association and dissociation constants (kass and kdissl 
for each compound with ibuprofen. Constants were correlated to temperature profile with a 
respective constant values found in literature (Hage, 1995). 
It was found that 95% of equilibrium in competitive binding would be reached by 0.5 seconds 
after introduction of the fatty acids, according to the considered parameters of the model. As 
shown in the Figure 19, the summed binding of the three compounds never exceed the total 
number of binding sites available, indicating appropriate relationships between separate 
compound calculations. Similar comparisons were made between bound and unbound 
compounds to find the same conservations within the calculations, further supporting validity 
of the model within the scope of considerations. Equilibrium seemed to follow temperature 
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Figure 19. Compound abundance in moles over time; compounds preceded by fare "free", 
compounds preceded by bare "bound"; Summed binding is given to compare with 
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Figure 20. Temperature profile for the skin at 1 mm depth 
Model of Diffusion of Ibuprofen 
In this model, concentration of ibuprofen was calculated in terms of time, x direction and z 
direction. The diffusion of ibuprofen across skin was dependent on the previous two models 
discussed: heat transfer from the drug delivery system device and the concentration of 
ibuprofen after being displaced by fatty acid. A top section of the arm was assumed to be a 
cube. The diffusion coefficient D was calculated as a function of temperature from the heat 
transfer model using the equation: 
D = kBT 
6rrµr 0 
Where k8 is the Boltzmann constant, Tis the temperature,µ is the viscosity of the gel at surface 
temperature, and r0 is the molecular radius of ibuprofen. 
Fick's Law of Diffusion,~~= D ::; , was used to derive an equation to calculate the 
concentration of ibuprofen that diffuses across skin in 2D model. The equation was derived to 
be: 
[
ci-1 1·+1 k - 2ci-1 1-k+ci-1 1·-1 k ci-1 1-k+1 - 2ci-1 1-k + ci-1 1-k-1] C- · = dt * D ' ' ' ' ' ' + ' ' ' ' ' ' + C- · 
i,1,k dx 2 dz 2 i-1,1,k 
Where C is the concentration of ibuprofen across skin, Dis the diffusion coefficient, dt is the 
change of time, dx is the change in position with respect to x and dz is the change in position 
with respect to z. 
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The transport of ibuprofen through skin will be assumed to be a direct diffusion through 
stratum corneum instead of through hair follicles and ducts. In addition, the change in the 
concentration of ibuprofen in the gel is minimal, therefore, the flux is assumed to be Oat the 
gel-skin interface. 
The ibuprofen diffusion gradient over time is given in Figure 21. The diffusion gradient accounts 
for the temperature profile and drug displacement within the model. There is an initial sharp 
slope, and the diffusion becomes more gradual as the difference between depths decreases. 
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Figure 21. Concentration of ibuprofen with respect to skin depth over time 
FINAL DESIGN 
As stated in the objectives section of this report, the overall goal of this project is to design a 
product that will transdermally deliver drugs to an affected area using a two gel system, one 
with the protein-drug complex and the other with a displacement factor, and a device that 
provides heating and ultrasound. 
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The final design for drug delivery is a two gel system with one gel that carries the drug payload, 
and another gel to displace the drug at time of application. The system is designed for a 1 ml 
gel application, 0.5 ml of each type. A model drug, ibuprofen, is bound with human serum 
albumin and suspended in a guar gum gel. The ibuprofen concentration is 40 mg/ml, 5% of the 
prescribed oral dose (400 mg). Drug complexation was performed with 90 mg/ml human serum 
albumin. The guar gum was prepared by the dissolution of 3 grams guar gum per 100 ml of 
water at 80 C. The 10:1 mass ratio of fish oil to HSA was prepared for the displacing gel by 
blending 900 mg fish oil per ml gel. 
In conjunction with the two gel system, the device will serve as a facilitator in the diffusion of 
the drug through the skin. The device consists of two major parts: a heating element and an 
ultrasound. The heating element facilitates drug diffusion by opening up the pores in the skin as 
well as relaxing the surrounding tissues. The ultrasound also helps in opening of the pores, but 
it also provides a therapeutic component. As seen in Figure 22, the final ultrasound holder 
design is incorporated, however its base was removed in order to reduce the size of the overall 
device. The final device was designed to contain an LCD screen (opening at the top), three LED 
status indicators (small holes to the left of the LCD opening), a large beveled opening to 
maximize ultrasound contact with the skin, and an opening where the ultrasound can be 
placed, therefore providing the user with a substantial handle to maneuver the device (square 
opening in front of ultrasound holder). Underneath the device is a recessed space for the 
copper sheet, the heating pad within the PDMS, and the temperature probe (to make sure the 
device does not exceed 40 °C). As can be seen, this device has the ability to hold all the 
necessary components, to be easily manipulated and moved around, to be very user-friendly, 
and most of all, to help promote localized transdermal drug delivery of ibuprofen. 
Figure 22. The fifth and final design of the device. 
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EVALUATION OF FINAL DESIGN 
The two-gel system met drug binding and release criteria. The criterion for drug binding in this 
project was a 20% reduction in HSA fluorescence at 320 nm. Binding was verified with a mean 
decrease of 35.3% in fluorescence of HSA by the use of fluorometer as shown in Table 16. 
Table 16. Resulting fluorescence of free ibuprofen, pure albumin, and an ibuprofen/albumin 
solution at 325 nm 
Mean Standard 
Std Err Mean% 





HSA 61651 2981 3.00 1721 
HSA + IBP 39913 3054 3.00 1763 0.01 0.0065 35.3 
Drug release was ensured through LC-MS/MS analysis before and after displacement 
treatment. The criterion for drug release was a 50% release of bound ibuprofen concentration. 
After ibuprofen displacement by fatty acid, it was revealed that there was a 51.5% mean 
release of bound ibuprofen from HSA as shown in Table 17. This confirmed that our criterion 
for drug release was met. 
Table 17. Ibuprofen concentrations for LC-MS/MS measurement in aqueous solutions; 





Standard Standard {Change 
Percent Standard 
Cone. 
Deviation Error a from 
Ibuprofen Deviation 




Unbound Samples 16.05 0.0958 0.0553 0.05 N/A 
Bound Samples 14.22 0.0581 0.0335 0.05 0.0159 
Displaced Samples 15.23 0.0578 0.0334 0.05 0.0471 51.45 10.25 
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In terms of the device, the criteria have been completely met. When 11 volts of energy are 
applied to the heating element, it heats up to 40 degrees C (and above) in only two minutes. As 
shown in Table 18, each run had a time below the expected two minutes (120 seconds). The 
mean time for the three runs was around 100 seconds with a standard deviation of 12 seconds; 
therefore, the heating element meets the original criteria. Figure 23 demonstrates this as well. 
Because the ultrasound holder was designed to maximize the contact between the ultrasound 
and the skin, it was concluded that this criteria was successfully met. In addition, when the 
ultrasound was placed on the holder (as well as on the holder of the 3D printed device), it was 
obvious that the ultrasound head had direct contact with the skin, thus further meeting the 
specified criteria. Since the device was designed to be both noninvasive as well as having the 
ability to be applied anywhere on the body, it can be said that this design meets the 
noninvasive and versatility requirements. 
Table 18. irime distribution for three different runs of the heating element. 
Temperature (degrees C) Run 1 (sec) Run 2 (sec) Run 3 (sec) 
30 0 0 0 
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Mean Time (sec) 
Std. Dev (sec) 
100.67 
12.66 
Temperature Profile of Heating 
Element 
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Figure 23. Temperature profile of a heating pad during three timed runs. 
In addition, tissue testing with the use of porcine skin layer demonstrated that treatment using 
the gel containing the drug complex increased the average cell population of 3T3 fibroblast cell 
culture. Tissue testing further supported the displacement of ibuprofen from HSA by fatty acid 
and that the designed drug delivery system was successful. 
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